10 Result(s)
within
Jordi Codony-Servat
-
Article
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer
The FAS/FASL system, comprising membrane-bound (mFAS and mFASL) and soluble forms (sFAS and sFASL), has been related to apoptosis driven by chemotherapy administration. In vitro experiments show chemotherapy u...
-
Article
Open AccessBIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expressio...
-
Article
Open AccessConvergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb t...
-
Article
Open AccessNuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal an...
-
Article
Open AccessAURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or othe...
-
Article
Open AccessTargeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
p21-activated kinase 1 (PAK1) stimulates growth and metastasis in non-small cell lung cancer (NSCLC). Protein kinase C iota (PKCι) is an enzyme highly expressed in NSCLC, regulating PAK1 signaling. In the pres...
-
Article
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial clinical benefit, but almost ...
-
Article
Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is effective against the EGFR T790M mutation in patients with advanced non-small-cell lung cancer ...
-
Article
Open AccessAuthor Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
-
Article
Open AccessKRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overal...
